文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells.

作者信息

Chang Jun, Cho Jae-Ho, Lee Seung-Woo, Choi So-Young, Ha Sang-Jun, Sung Young-Chul

机构信息

Division of Molecular and Life Science, National Laboratory of DNA Medicine, Pohang University of Science and Technology, Hyoja-Dong, Pohang, Kyungbuk, Republic of Korea.

出版信息

J Immunol. 2004 Mar 1;172(5):2818-26. doi: 10.4049/jimmunol.172.5.2818.


DOI:10.4049/jimmunol.172.5.2818
PMID:14978082
Abstract

Antigenic and costimulatory signals trigger a developmental program by which naive CD8 T cells differentiate into effector and memory cells. However, initial cytokine signals that regulate the generation of effector and memory CD8 T cells are not well understood. In this study, we show that IL-12 priming during in vitro antigenic stimulation results in the significant increase of both primary and memory CD8 T cell population in mice after adoptive transfer of activated cells. The effect of IL-12 priming is closely associated with qualitative changes in CD8 T cells, such as reduced MHC I tetramer binding and CD69 expression, altered distribution of lipid rafts, decreased cytolytic activity, and less susceptibility to apoptosis. Furthermore, exogenous IL-12 priming improved the intrinsic survival properties of memory CD8 T cells, leading to better protective immunity and vaccine-induced memory CD8 T cell responses. However, the experiments with IL-12p40- and IL-12Rbeta1-deficient mice showed similar levels of primary and memory CD8 T cell responses compared with wild-type mice, implying that endogenous IL-12 and/or IL-12R signaling in vivo is not critical for CD8 T cell immunity. Together, our results suggest that IL-12 can serve as an important, but dispensable regulatory factor for the development of CD8 T cells, and IL-12 priming could be useful in many medical applications.

摘要

相似文献

[1]
IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells.

J Immunol. 2004-3-1

[2]
Phenotypic changes induced by IL-12 priming regulate effector and memory CD8 T cell differentiation.

Int Immunol. 2007-9

[3]
Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.

J Immunol. 2002-11-1

[4]
Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.

J Immunol. 2004-2-1

[5]
Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset.

J Immunol. 2005-5-1

[6]
Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.

J Immunol. 2006-11-15

[7]
Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance induction.

J Immunol. 2008-2-15

[8]
IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15.

J Immunol. 2012-5-11

[9]
Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

J Immunol. 2000-10-15

[10]
Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.

J Immunol. 2005-7-15

引用本文的文献

[1]
Advanced progress in the genetic modification of the oncolytic HSV-1 virus.

Front Oncol. 2025-1-21

[2]
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.

Oncoimmunology. 2023

[3]
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Mol Ther. 2022-6-1

[4]
Localized Interleukin-12 for Cancer Immunotherapy.

Front Immunol. 2020

[5]
Prostaglandin E in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8 T cells.

Cancer Immunol Immunother. 2020-2-25

[6]
Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.

Nat Commun. 2019-11-13

[7]
IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.

Cancer Res. 2019-5-29

[8]
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Oncoimmunology. 2017-1-31

[9]
IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.

Cancer Gene Ther. 2015-7

[10]
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.

Cancer Immunol Immunother. 2015-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索